Beyond tissue concentrations: antifungal penetration at the site of infection
- PMID: 30816968
- PMCID: PMC6506603
- DOI: 10.1093/mmy/myy067
Beyond tissue concentrations: antifungal penetration at the site of infection
Abstract
Despite advances in antifungal therapy, invasive fungal infections remain a significant cause of morbidity and mortality worldwide. One important factor contributing to the relative ineffectiveness of existing antifungal drugs is insufficient drug exposure at the site of infection. Despite the importance of this aspect of antifungal therapy, we generally lack a full appreciation of how antifungal drugs distribute, penetrate, and interact with their target organisms in different tissue subcompartments. A better understanding of drug distribution will be critical to guide appropriate use of currently available antifungal drugs, as well as to aid development of new agents. Herein we briefly review current perspectives of antifungal drug exposure at the site of infection and describe a new technique, matrix-assisted laser desorption ionization (MALDI) mass spectrometry imaging, which has the potential to greatly expand our understanding of drug penetration.
Keywords: MALDI imaging; antifungals; drug quantification; posaconazole; site of infection; tissue penetration.
© The Author(s) 2019. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.
Figures



Similar articles
-
A Novel, Rapid, and Low-Volume Assay for Therapeutic Drug Monitoring of Posaconazole and Other Long-Chain Azole-Class Antifungal Drugs.mSphere. 2018 Dec 19;3(6):e00623-18. doi: 10.1128/mSphere.00623-18. mSphere. 2018. PMID: 30567902 Free PMC article.
-
Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients.Expert Opin Drug Metab Toxicol. 2019 Nov;15(11):881-895. doi: 10.1080/17425255.2019.1671971. Epub 2019 Oct 30. Expert Opin Drug Metab Toxicol. 2019. PMID: 31550939 Review.
-
Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease.Antimicrob Agents Chemother. 2019 May 24;63(6):e00524-19. doi: 10.1128/AAC.00524-19. Print 2019 Jun. Antimicrob Agents Chemother. 2019. PMID: 30988140 Free PMC article.
-
Antifungal drugs: An updated review of central nervous system pharmacokinetics.Mycoses. 2020 Oct;63(10):1047-1059. doi: 10.1111/myc.13157. Epub 2020 Sep 4. Mycoses. 2020. PMID: 32772402 Review.
-
Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model.Antimicrob Agents Chemother. 2017 Sep 22;61(10):e01009-17. doi: 10.1128/AAC.01009-17. Print 2017 Oct. Antimicrob Agents Chemother. 2017. PMID: 28739797 Free PMC article.
Cited by
-
The Use of Tissue Concentrations of Biological and Small-Molecule Therapies in Clinical Studies of Inflammatory Bowel Diseases.Pharmaceutics. 2024 Nov 22;16(12):1497. doi: 10.3390/pharmaceutics16121497. Pharmaceutics. 2024. PMID: 39771479 Free PMC article. Review.
-
Diatomaceous earth/zinc oxide micro-composite assisted antibiotics in fungal therapy.Nano Converg. 2021 Oct 25;8(1):32. doi: 10.1186/s40580-021-00283-6. Nano Converg. 2021. PMID: 34694514 Free PMC article.
-
Potential Implication of Azole Persistence in the Treatment Failure of Two Haematological Patients Infected with Aspergillus fumigatus.J Fungi (Basel). 2023 Jul 30;9(8):805. doi: 10.3390/jof9080805. J Fungi (Basel). 2023. PMID: 37623576 Free PMC article.
-
Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin.Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1523-1526. doi: 10.1007/s10096-025-05117-5. Epub 2025 Mar 31. Eur J Clin Microbiol Infect Dis. 2025. PMID: 40163284
-
How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions.Clin Infect Dis. 2020 Jul 27;71(3):685-692. doi: 10.1093/cid/ciz1195. Clin Infect Dis. 2020. PMID: 32170948 Free PMC article.
References
-
- Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012; 4: 165rv113. - PubMed
-
- Pappas PG, Kauffman CA, Andes DR et al. . Executive summary: Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 62: 409–417. - PubMed
-
- Heidelberger C, Chaudhuri NK, Danneberg P et al. . Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957; 179: 663–666. - PubMed
-
- Grunberg E, Titsworth E, Bennett M. Chemotherapeutic activity of 5-fluorocytosine. Antimicrob Agents Chemother (Bethesda). 1963; 161: 566–568. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources